Literature DB >> 24980644

What are the factors that affect survival and relapse after local recurrence of osteosarcoma?

Akihiko Takeuchi1, Valerae O Lewis, Robert L Satcher, Bryan S Moon, Patrick P Lin.   

Abstract

BACKGROUND: Despite improvements in treatment of primary osteosarcoma, treatment of patients who have local recurrence is not well defined. QUESTIONS/PURPOSES: We asked: (1) What are the 5- and 10-year overall survival rates of patients with osteosarcoma who have a local recurrence? (2) What factors are associated with better survival after a local recurrence? (3) Does chemotherapy affect overall survival after local recurrence? (4) What are the rates of rerecurrence after amputation and with limb salvage?
METHODS: We reviewed 45 patients with nonmetastatic conventional high-grade osteosarcoma who had local recurrence between 1985 and 2007, during which time 461 patients were treated for the same disease. Seven patients with known local recurrence were lost to followup and not included in our study. The median age of the patients was 18 years, and minimum followup was 2 months (median, 39 months; range, 2-350 months). The primary tumor was located in the extremity in 36 patients and the pelvis in nine. The median time from initial surgery for resection or amputation of the primary tumor to local recurrence was 18 months (range, 2-149 months). Ten recurrences developed in bone and 35 in soft tissue. In 21 of the latter cases, the soft tissue recurrence was undetectable on conventional radiographs. Prognostic factors for overall patient survival after recurrence were evaluated by Kaplan-Meier survival and Cox multivariate analyses.
RESULTS: Overall postrecurrence patient survival was 30% at 5 years and 13% at 10 years. Cox multivariate analysis revealed that concurrent metastasis (relative risk = 4, p = 0.003) and recurrent tumor size 5 cm or larger (relative risk = 13, p < 0.0001) were independent predictors of worse survival. With the numbers available, treatment with chemotherapy after local recurrence was not associated with better survival (p = 0.54). Nine patients had a second local recurrence, and the actuarial risk of rerecurrence was 34% at 5 years. There was no difference in the frequency of rerecurrence between patients treated by amputation and wide local excision (p = 0.23).
CONCLUSIONS: The long-term prognosis of patients who have local recurrence of osteosarcoma is poor. Followup beyond 5 years is essential, because the disease can have a protracted course. Most recurrences develop in soft tissue and are difficult to see on plain radiographs alone. The size of the recurrence and presence of metastasis were independent prognostic factors, suggesting that early detection may be important. Chemotherapy did not have a significant effect on survival, and surgical eradication of recurrence with wide margins may be critical to maximizing the chances for survival.

Entities:  

Mesh:

Year:  2014        PMID: 24980644      PMCID: PMC4160478          DOI: 10.1007/s11999-014-3759-7

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  29 in total

1.  High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance.

Authors:  Norman Jaffe; Richard Gorlick
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

2.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

Authors:  Stefan S Bielack; Beate Kempf-Bielack; Günter Delling; G Ulrich Exner; Silke Flege; Knut Helmke; Rainer Kotz; Mechthild Salzer-Kuntschik; Matthias Werner; Winfried Winkelmann; Andreas Zoubek; Heribert Jürgens; Kurt Winkler
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

Authors:  K Winkler; G Beron; G Delling; U Heise; H Kabisch; C Purfürst; J Berger; J Ritter; H Jürgens; V Gerein
Journal:  J Clin Oncol       Date:  1988-02       Impact factor: 44.544

4.  Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur.

Authors:  M A Simon; M A Aschliman; N Thomas; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1986-12       Impact factor: 5.284

5.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement.

Authors:  A G Huvos; G Rosen; R C Marcove
Journal:  Arch Pathol Lab Med       Date:  1977-01       Impact factor: 5.534

6.  Outcome after local recurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000).

Authors:  Carlos Rodriguez-Galindo; Nirali Shah; M Beth McCarville; Catherine A Billups; Michael N Neel; Bhaskar N Rao; Najat C Daw
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

7.  Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy.

Authors:  G Bacci; S Ferrari; A Longhi; S Perin; C Forni; N Fabbri; N Salduca; M Versari; K V Smith
Journal:  Eur J Cancer       Date:  2001-01       Impact factor: 9.162

8.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli.

Authors:  M Campanacci; G Bacci; F Bertoni; P Picci; A Minutillo; C Franceschi
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

10.  Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy.

Authors:  F Duffaud; L Digue; C Mercier; J P Dales; M Baciuchka-Palmaro; F Volot; P Thomas; R Favre
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more
  14 in total

1.  MRI Identification of the Osseous Extent of Pediatric Bone Sarcomas.

Authors:  Matthew J Thompson; John C Shapton; Stephanie E Punt; Christopher N Johnson; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

2.  Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.

Authors:  Kyoung Jin Chang; Chang-Bae Kong; Wan Hyeong Cho; Dae-Geun Jeon; Soo-Yong Lee; Ilhan Lim; Sang Moo Lim
Journal:  Skeletal Radiol       Date:  2014-11-29       Impact factor: 2.199

3.  Comparable outcomes of recycled autografts and allografts for reconstructions in patients with high-grade osteosarcoma.

Authors:  Kuan-Lin Chen; Chao-Ming Chen; Cheng-Fong Chen; Yu-Chi Cheng; Yu-Kuan Lin; Shang-Wen Tsai; Tain-Hsiung Chen; Po-Kuei Wu; Wei-Ming Chen
Journal:  Int Orthop       Date:  2021-08-19       Impact factor: 3.075

4.  How Do the Outcomes of Radiation-Associated Pelvic and Sacral Bone Sarcomas Compare to Primary Osteosarcomas following Surgical Resection?

Authors:  Alexander L Lazarides; Zachary D C Burke; Manit K Gundavda; Rostislav Novak; Michelle Ghert; David A Wilson; Peter S Rose; Philip Wong; Anthony M Griffin; Peter C Ferguson; Jay S Wunder; Matthew T Houdek; Kim M Tsoi
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

5.  Developing an Evidence-based Followup Schedule for Bone Sarcomas Based on Local Recurrence and Metastatic Progression.

Authors:  Cara Cipriano; Anthony M Griffin; Peter C Ferguson; Jay S Wunder
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

6.  Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group.

Authors:  Holly L Spraker-Perlman; Donald A Barkauskas; Mark D Krailo; Paul A Meyers; Cindy L Schwartz; John Doski; Richard Gorlick; Katherine A Janeway; Michael S Isakoff
Journal:  Pediatr Blood Cancer       Date:  2018-09-25       Impact factor: 3.167

7.  The Significance of a "Close" Margin in Extremity Sarcoma: A Systematic Review.

Authors:  Ike Hasley; Yubo Gao; Amy E Blevins; Benjamin J Miller
Journal:  Iowa Orthop J       Date:  2018

Review 8.  Team Approach: Osteosarcoma of the Distal Part of the Femur in Adolescents.

Authors:  Russell N Stitzlein; John Wojcik; Ronnie A Sebro; Naomi J Balamuth; Kristy L Weber
Journal:  JBJS Rev       Date:  2017-12

9.  Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography Results in Negative Surgical Margins and Decreased Local Recurrence in an Orthotopic Mouse Model of Osteosarcoma.

Authors:  Adel Mahjoub; Alejandro Morales-Restrepo; Mitchell S Fourman; Jonathan B Mandell; Lu Feiqi; Margaret L Hankins; Rebecca J Watters; Kurt R Weiss
Journal:  Ann Surg Oncol       Date:  2018-12-27       Impact factor: 5.344

10.  Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.

Authors:  Fanxiao Liu; Qingyu Zhang; Dezhi Zhu; Fengxia Liu; Zhenfeng Li; Jianmin Li; Bomin Wang; Dongsheng Zhou; Jinlei Dong
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.